From SourceWatch
Jump to navigation Jump to search

Herceptin (Trastuzumab) is drug for the treatment of breast cancer.

Herceptin PR

In March 2000 PR Week that Laura A. Leber, the Vice president, corporate communications for Genentech described her as the architect of early PR on Herecptin. "With the promotion of Herceptin, a treatment for breast cancer, Leber pioneered the company’s advocate-relations efforts by creating the first program designed to provide patients access to experimental drugs." [1] (Sub req'd)

In February 2001 PR Week reported that Ketchum had "won the UK brief to promote Roche UK's oncology prescription drugs Herceptin." [2]

Other SourceWatch Resources

External links

This article is a stub. You can help by expanding it.